 This observational study will evaluate the patterns of disease progression in patients with locally advanced or metastatic non-small cell lung cancer NSCLC harbouring EGFR activating mutations receiving Tarceva erlotinib as first-line treatment. Patients will be followed for up to 12 months after progression of disease. 